Reslizumab (Cinqair) | 合法藥品大搜索
Reslizumab(Cinqair).OFFICEADMININSTRATION.IndicationsforPriorAuthorization:SevereEosinophilicAsthma.Allofthefollowingmustbemetasa ...
CINQAIR (reslizumab)
OFFICE ADMININSTRATION
Indications for Prior Authorization:
All of the following must be met as a condition(s) for coverage:
Must be prescribed AND followed by a pulmonologist or immunologist, AND Patient must be at least 18 years of age, AND Eosinophil blood count of ≥ 150 cells µL within last 6 weeks or ≥ 300 cells/µL within the last 12 months, AND Patient had inadequate response to a high-dose inhaled corticosteroid in combination with long-acting beta agonist [LABA] and has been compliant with therapy for at least 3 months, AND Patient meets one of the following within the past year: One or more acute asthma-related ED visit(s) One or more acute inpatient visits where asthma was the principle diagnosis Use of chronic systemic steroids...
reslizumab covid reslizumab covid b12的功效 中國化學製藥股份有限公司ptt 合利他命種類 "元宙" 樂妊芬膠囊５０毫克（可洛米分） 黴癒療黴舒 胃喜因懸浮液 胃喜因哪裡買 抗組織胺腎臟
COVID | 合法藥品大搜索
由 S Hanon 著作 · 2020 · 被引用 17 次 — In a cohort of severe asthma patients, a small number of COVID-19 cases was ... in Belgium are omalizumab, mepolizumab, benralizumab and reslizumab, while ... Read More
Poor outcome of SARS | 合法藥品大搜索
由 K Eger 著作 · 2021 · 被引用 13 次 — ... and disease course of COVID-19 in patients with severe asthma on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, ... Read More
Reslizumab (Intravenous Route) Description and Brand ... | 合法藥品大搜索
COVID-19: Advice, updates and vaccine options ... Reslizumab (Intravenous Route) ... Reslizumab injection is used with other medicines for the maintenance ... Read More
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 ... | 合法藥品大搜索
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With ... Read More
Poor outcome of SARS-CoV | 合法藥品大搜索
由 K Eger 著作 · 被引用 13 次 — ... severe course of COVID-19 compared to the general population. ... reslizumab, benralizumab, dupilumab), as compared with COVID-19 data ... Read More
LitCovid - NCBI | 合法藥品大搜索
2021年1月4日 — ... and disease course of COVID-19 in patients with severe asthma on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, ... Read More
Asthma, biologics | 合法藥品大搜索
由 AT Akenroye 著作 · 2020 · 被引用 17 次 — ... of COVID-19 may differ. Omalizumab (an anti–immunoglobulin E [IgE] antibody), mepolizumab and reslizumab (which block interleukin [IL] 5) ... Read More
Anti-IL5 Drugs in COVID-19 Patients | 合法藥品大搜索
由 D Pala 著作 · 2021 — In severe COVID-19 patients, the blockade of eosinophils' activation might ... Anti-IL-5 drugs (benralizumab, mepolizumab, reslizumab) are ... Read More
Eosinophilic Disorders Patients | 合法藥品大搜索
Patients on eosinophil-depleting drugs, such as benralizumab, mepolizumab, and reslizumab, as well as patients on dupilumab, have not been reported to have ... Read More
Reslizumab (Cinqair) | 合法藥品大搜索
Reslizumab (Cinqair). OFFICE ADMININSTRATION. Indications for Prior Authorization: Severe Eosinophilic Asthma. All of the following must be met as a ... Read More
相關資訊整理
【肺昇朗注射液劑30毫克】FASENRA適用於嗜酸性白血球表現型的嚴重氣喘成人病人，做為附加維持治療。
藥品名稱:肺昇朗注射液劑30毫克許可證字號:衛部菌疫輸字第001101號許可證種類:菌 疫適應症:FASENRA適用於嗜酸性白血球表現...
【舒肺樂注射劑100毫克/毫升】嚴重氣喘之維持治療：表現型為嗜伊紅性白血球的嚴重氣喘且控制不良(severe refractory eosinophilic asthma)之12歲以上病人之附加維持治療。嗜伊紅性肉芽腫併多發性血管炎：治療嗜伊紅性肉芽腫併多發性血管炎[eosinophilic granulomatosis with polyangiitis (EGPA)]之成人病人。
藥品名稱:舒肺樂注射劑100毫克/毫升許可證字號:衛部菌疫輸字第001144號許可證種類:菌 疫適應症:嚴重氣喘之維持治療：表現型...